Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99Tc-MDP vs calcium for osteopenia during TSH suppression in postmenopausal differentiated thyroid carcinoma
ChiCTR2200064170Phase 4Not yet recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Sep 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of technetium-99m-methylene diphosphonate in osteopenia (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Bone mineral density. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
technetium-99m-methylene diphosphonate
03
Conditions
osteopenia
Beyond the preview
Go deeper on ChiCTR2200064170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064170.